Puerarin inhibits titanium particle‐induced osteolysis and RANKL‐induced osteoclastogenesis via suppression of the NF‐κB signaling pathway

Abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway

“…Our data showed that puerarin significantly down regulated c-Fos gene expression, while did not suppress the expression of NF-κB and phosphor–NF–κB, and the overall outcome was that gene and protein expressions of NFATc1 were not inhibited by puerarin, which was consisted with a previous study [ 21 ]. However, two recently published articles from the same group reported a different finding, which indicated that puerarin (100 ​μM) suppressed osteoclastogenesis via inhibition of NF-κB signaling pathways in both osteoclast of RANKL-induced BMMs and RAW264.7 ​cells [ 17 , 18 ]. Although they reported that F-actin ring formation and bone resorption were also decreased by puerarin, the authors consider these as the cascade events following the suppression of osteoclastogenesis.…”

“…Our previous study found that puerarin promoted osteogenesis and inhibited adipogenesis in vitro [ 15 ]. It was reported puerarin prevented the OVX-induced bone loss by inhibiting osteoclastogenesis [ [16] , [17] , [18] , [19] ]. A recent study suggested puerarin suppressed osteoclastogenesis via NF-κB signaling pathway [ 18 , 20 ].…”

Puerarin—an isoflavone with beneficial effects on bone health

“…Research results published in 2020 also indicated that puerarin (15.4 and 30.8 mg/kg/d) administered i.p. inhibits titanium particleinduced osteolysis [44]. Zhang et al [34], on the other hand, proved that calvarial injection of puerarin (1 mg/kg/d) is capable of inhibiting LPS-induced bone loss.…”

“…The essence of the presented results of puerarin studies in animal models is presented in Table 2 (Ref. [21,22,26,34,35,[38][39][40][41][42][43][44][45][46][47][48][49][50][52][53][54][55][56]).…”

Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways

“…A growing body of evidence suggests that anti-osteoclastogenesis is a potential therapy strategy [ 6 ]. Many drugs such as Denosumab and Zoledronic Acid have been developed to inhibit osteoclastogenesis and, thereby, treat particle-induced peri-implant osteolysis [ 7 ]. However, these clinical drugs have been found to bring a series of side effects to patients after long-term use, including digestive system disorders, osteonecrosis, and even some types of malignancy [ 8 , 9 , 10 ].…”